DOCSLIB.ORG

Medicines in Europe: the Most Important Changes in the New Legislation

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Medicines in Europe: the Most Important Changes in the New Legislation 83 boulevard Voltaire - (F)75558 PARIS CEDEX 11 - Tél. : 33 1 49 23 72 80 / Fax : 33 1 48 07 87 32 N°1004 LA REVUE Translated from Rev Prescrire July-August 2004; 24 (252): 481. Medicines in Europe: the most important changes in the new legislation As we digest the results of the European elec- But we must not drop our guard: patients, tions and the last-minute agreement on the health professionals,consumers,health insurers European Constitution, the drafting process of and concerned politicians still have to ensure that the new legislative framework on medicines for the “competent authorities” fulfil their new human use reminds us once again that European obligations and make the pharmaceutical citizens’ voices can and must be heard. industry respect the legal framework that For more than two years the pharmaceutical European society has chosen for it. majors and their lobbyists took it for granted that “Europe” is not some distant land,but is at the they could obtain made-to-measure legislation heart of many of the most important decisions supporting their own narrow financial that shape our society.And Europe is neither ÉDITORIAL Action bears fruit interests, with scant regard for public health inaccessible nor incomprehensible:we just have or for the economic survival of national health to roll up our sleeves and make sure that care systems. special interest groups are not given a free hand. What they failed to realise was that Euro- Finally, Europe is not “too technical”: each new pean citizens from all quarters, including this dossier implies important choices for society. Journal, its subscribers, the “Association Mieux Europe was founded on the notions of free Prescrire” and the diverse member organisa- trade and free circulation,and was bolstered by tions of the Medicines in Europe Forum would the successful introduction of a single currency. come together to scrutinise the draft texts, In future,“Europe” will be increasingly synony- explain the stakes, sound the alarm, make mous with welfare and public services, chief counter-proposals, meet with European among which is health care.Many battles remain, deputies, and lobby ministers. given the inevitable clashes between major What we achieved together was a major financial interests and basic human health needs? change of perspective: in the end, European We offer our congratulations to all those who legislators endorsed the view that medicines contributed to correcting the course of Euro- are not just another consumer good.The drafts pean legislation on medicinal products. And underwent major improvements, not least we stand shoulder to shoulder with all those ensuring greater transparency on the part of defending accessible, high-quality health care. medicines agencies. ©Prescrire International PRESCRIRE INTERNATIONAL AUGUST 2004/VOLUME 13 N° 72 • PAGE 158-1 Ouvertures e UROPE Translated from Rev Prescrire July-August 2004; 24 (252): 542-548. Medicines in Europe: citizens’ successes G The new European legislative uropean harmonisation on medici- ed extracts on Prescrire website, www. framework for human medicines was nal products started in the 1960s, prescrire.org). A joint position was published on 30 April 2004, after a Ewith the founding Directive finally adopted by the Council of procedure lasting more than two 65/65/EC. It continued over subsequent Ministers on 3 June 2003 (8). years. years, notably with the creation of the In late 2003, deputies and ministers European Medicines Evaluation Agency again came under pressure, notably from G The stakes were high, as the new in 1995 (1). the Enterprise Directorate-General and texts determine the level of After multiple additions and amend- industry representatives, to complete their guarantees offered to EU citizens on ments, two major texts, valid until 2003, work before the new member states joined marketing authorisation, risk set out the legislative framework for the Union. The last compromises, management and information on medicinal products: namely Directive adopted on 17 December 2003, were medicines. 2001/83/EC, instituting the community reached after hasty negotiations. code on medicines for human use G Patients, consumers, health (grouping together the provisions of As a result, the final Directive and professionals and health insurance previous Directives); and Regulation Regulation, published in the Official organisations joined forces, notably 2309/93, establishing community Journal of the European Union on within the Medicines in Europe procedures and creating the European 30 April 2004 (10,11), differ substantial- Forum, to make their views heard Medicines Evaluation Agency (2,3). ly from the initial drafts. We list the most and to act as a counterweight to the The European Commission, which important changes affecting patients and powerful pharmaceutical lobby. initiates legislative changes, presented health care professionals, comparing two drafts: one to replace the 2001 the new text with the previous wording, G The citizens’ lobby made several Directive, and one to replace the 1993 and pointing out the most negative pro- noteworthy gains, especially Regulation. The Enterprise Directorate- posals that were ultimately rejected (b). regarding medicines agencies’ General of the European Commission is transparency. But pharmaceutical responsible for matters relating to medic- majors, with support from the inal products. Its overriding aims were to Transparency of medicines agen- European Commission’s Enterprise make the European pharmaceutical cies: unprecedented obligations Directorate-General, succeeded in industry more competitive, and to ensure ensuring that the notion of “ added that the single European market contin- therapeutic value” will not be taken ued to function after EU expansion on The main change concerns transparency into account when considering 1 May 2004. The draft texts placed too obligations by medicines agencies, which whether or not to authorise new much stress on relaxing marketing was barely an issue in the previous texts. drugs, and that the “clinical data authorisation procedures and permitting protection period” will be even advertising, while largely overlooking National agencies: public access longer than before. public health concerns (1,4). to the agendas and reports of meet- ings, and to assessment reports. The G EU citizens must remain The European Commission had to Directive now requires that “member mobilised to ensure that the texts are revise its work. The two new texts were states shall ensure that the competent author- effectively enacted in national adopted through the co-decision proce- ity (i.e. the national medicines agency) makes legislation and are strictly applied in dure, involving the European Parliament publicly accessible its rules of procedure and patients’ best interests.We must also and the Council of Ministers (a). This those of its committees, agendas for its meet- be on the lookout for the tricks that procedure took more than two years, ings and records of its meetings, accompa- the drug companies will inevitably from late 2001 to early 2004 (1,4-9). nied by decisions taken, details of votes and employ to preserve their financial At the first reading by the European explanations of votes, including minority interests. Parliament, in 2002, deputies adopted opinions” (D article 126b). It further stip- many amendments intended to place the ulates that the competent authorities accent on public health, despite strong will make marketing authorisation pressure from the industry lobby (6). “publicly accessible”, “without delay”, Some European health ministers subse- together with the assessment report Medicines in Europe : quently rejected a number of amend- and the underlying reason for their ments they thought might undermine the opinion provided separately for each the complete file is funding of national medicines agencies indication (D articles 21-3 and 21-4). available free in or the financial interests of their coun- tries’ drug companies. Others rallied to The European agency: public French and English defend patients’ interest, but the deter- access to all documents underlying on www.prescrire.org mined European Commission continued decisions. In the 2004 Regulation, to support the industrial sector (see select- almost all the articles concerning deci- PAGE 158-2 • PRESCRIRE INTERNATIONAL AUGUST 2004/VOLUME 13 N° 72 sions made by the European Medicines staff (…) responsible for granti- Evaluation Agency and the documents ng marketing authorisation, underlying these decisions mention an rapporteurs and experts (…), have obligation to make these documents no financial or other interests in available to the public (see below for the pharmaceutical industry details of each of the agency’s core tasks). which could affect their impar- In addition, article 73 of the 2004 tiality. These persons shall make Regulation stipulates that European an annual declaration of their Regulation 1049/2001 on public access financial interests” (D article to documents held by European insti- 126b). tutions now applies to the medicines The 2004 Regulation states agency. The agency is therefore required that the financial interests of to create a “register (…) to make available members of the management all documents that are publicly accessible board, committee members, (…)”, as is already the case for other insti- rapporteurs and European tutions. These registers were created to Medicines Evaluation Agency make documents easily accessible, even experts must
Load more

Recommended publications
  • Dec1 Untitled REF GUIDE FINAL[2]
    UNTITLED RESOURCE GUIDE SUGGESTIONS FOR ENGAGEMENT ABOUT UNTITLED Beginning with a reflection on the early AIDS epidemic, Untitled eschews a linear narrative to introduce a fractious timeline, moving from the sublime to the tragic and back again. By juxtaposing mainstream network news, activist footage, artists' work, and popular entertainment from the last turbulent decades, Untitled references regimes of power that precipitated a generation of AIDS and queer activism and continues today with international struggle and expression. In 2010, artist Jim Hodges was invited to give a lecture on the billboard project of Félix González-Torres at San Antonioʼs Artpace. He teamed up with fellow filmmakers Carlos Marques da Cruz and Encke King to create Untitled. Neither a portrait or a documentary about González- Torres, the film was an attempt to place the viewer “in his room,” that is to say, the filmmakers worked to create, for the viewer, an understanding of the influences and contexts within which González- UNTITLED Torres was working. In Hodges's words, “In this way, the framing of the artist can become a way to project any number of people, endlessly.” A Film by Untitled can therefore be considered to be as much about González- Jim Hodges, Carlos Marques da Cruz, and Encke King Torres and the AIDS crisis as it can be seen as grappling with the continuum of global dehumanization. PURPOSE OF THIS RESOURCE GUIDE In an effort to honor the sense of endlessness that Untitled suggests, this guide is a resource for provoking both public and private conversation. We have provided you with: • WORDS for engagement regarding HIV/AIDS, art, and culture • THOUGHTS to provoke dialogue • HIV/AIDS TIMELINE • INFORMATION about prevention and wellness • LINKS to extend the conversation CREDITS • Like the film, this Resource Guide hopes to raise more questions than it answers.
    [Show full text]
  • Curbing Unfair Drug Prices: a Primer for States by the Global Health Justice Partnership Is Licensed Under a Creative Commons Attribution 3.0 Unported License
    Curbing Unfair Drug Prices ________________________________________________ A Primer for States Global Health Justice Partnership Policy Paper August 2017 Global Health Justice Partnership of the Yale Law School and the Yale School of Public Health National Physicians Alliance Universal Health Care Foundation of Connecticut Lead Authors: Aaron Berman, Yale School of Public Health, 2017 Theodore Lee, Yale Law School, 2018 Adam Pan, Yale Law School, 2019 Zain Rizvi, Yale Law School, 2017 Arielle Thomas, Yale School of Public Health, 2017 Curbing Unfair Drug Prices: A Primer for States by the Global Health Justice Partnership is licensed under a Creative Commons Attribution 3.0 Unported License. It may be freely reproduced, as long as it is correctly attributed. Yale Global Health Justice Partnership Yale Global Health Justice Partnership The Yale Global Health Justice Partnership (GHJP) is a joint initiative between Yale Law School (YLS) and Yale School of Public Health (YSPH) that trains the next generation of scholars and practitioners to tackle the complex interdisciplinary challenges of global health. The GHJP works with international partners at the interface of law and governance, public health, and medicine to theorize, build analytical frameworks, create knowledge, and mobilize research to help drive the social change necessary for improving the health and wellness of people around the world. Learn more at www.yaleghjp.org. The GHJP offers a practicum course each year that engages students in real-world projects with scholars, activists, lawyers, and other practitioners on issues of health justice. Working papers are produced as a part of these projects, with students as lead authors. Final papers reflect input and revisions by GHJP faculty, partners, staff, and other readers.
    [Show full text]
  • Big Pharma Takes It
    A Public Eye Report – March 2021 Big Pharma takes it all How pharmaceutical corporations profiteer from their privileges – even in a global health crisis like COVID-19 1 COVID-19, SHOWCASE OF A PERVERTED BUSINESS MODEL 3 2 BIG PHARMA’S 10 STRATEGIES FOR CASHING IN 7 2.1 – Determine R & D priorities by potential profits alone 9 2.2 – Abuse patents to lock up knowledge, inflate prices and limit supply 10 2.3 – Direct the system towards the needs of high-income countries 13 2.4 – Avoid public accountability 16 2.5 – Design clinical trials for self-interest 18 2.6 – Socialise risks, privatise profits 20 2.7 – Embrace public investment, reject public returns 22 2.8 – Impose unjustifiable, unchallengeable prices 24 2.9 – Financialise innovation 29 2.10 – Lobby pervasively 31 3 SWITZERLAND IS ‘PHARMALAND’ 33 4 CONCLUSION: WHAT COVID-19 SHOWS US 37 5 TIME TO ACT: OUR DEMANDS 39 Endnotes 42 IMPRINT Big Pharma takes it all: How pharmaceutical corporations profiteer from their privileges – even in a global health crisis like COVID-19. A Public Eye Report, March 2021, 52 pages. | Authors Patrick Durisch, Gabriela Hertig | Contributors Christa Luginbühl, Oliver Classen | Edition Mary Louise Rapaud | Publishers Romeo Regenass, Ariane Bahri | Layout Karin Hutter, karinhutter.com | Icons opak.cc | Cover picture © Tang Ming Tung/Getty Images PUBLIC EYE Dienerstrasse 12, Postfach, CH-8021 Zurich | +41 (0)44 2 777 999 | [email protected] Avenue Charles-Dickens 4, CH-1006 Lausanne | +41 (0)21 620 03 03 | [email protected] Donations IBAN CH64 0900 0000 1001 0813 5, Public Eye | publiceye.ch 1 ��-19, showcase of a perverted business model Monty Rakusen/Keystone © 4 BIG PHARMA TAKES IT ALL “No one is safe until everybody is safe”, “leave no one behind” are mantras that have been oft repeated by state leaders and the World Health Organization (WHO) since the coronavirus pandemic turned our world upside down in spring, 2020.
    [Show full text]
  • The Structural Power of Strong Pharmaceutical Patent Protection in U.S. Foreign Policy
    Loyola University Chicago, School of Law LAW eCommons Faculty Publications & Other Works 2003 The trS uctural Power of Strong Pharmaceutical Patent Protection in U.S. Foreign Policy James T. Gathii Loyola University Chicago, School of Law, [email protected] Follow this and additional works at: http://lawecommons.luc.edu/facpubs Part of the Intellectual Property Law Commons, and the International Law Commons Recommended Citation James T. Gathii, The trS uctural Power of Strong Pharmaceutical Patent Protection in U.S. Foreign Policy, 7 J. Gender Race & Just. 267 (2003). This Article is brought to you for free and open access by LAW eCommons. It has been accepted for inclusion in Faculty Publications & Other Works by an authorized administrator of LAW eCommons. For more information, please contact [email protected]. The Structural Power of Strong Pharmaceutical Patent Protection in U.S. Foreign Policy James Thuo Gathii* While the Chief Justice's dissent says there are 'weapons [such as cartels or boycotts] in the arsenalsofforeign nations' sufficient to enable them to counter anticompetitive conduct ... such ... political remed[ies are] hardly available to a foreign nation faced with the monopolistic control of the supply of medicines needed for the health and safety of its people. I I. INTRODUCTION There are two distinct, albeit mutually reinforcing, stances within U.S. foreign policy on HIV/AIDS. The first of these stances favors strong international pharmaceutical patent protection, unencumbered by any restrictions, as the best alternative to ensuring availability of drugs to treat those infected with HIV/AIDS. 2 Unlike the first stance that is Assistant Professor, Albany Law School.
    [Show full text]
  • Pharmaceutical Direct-To-Consumer Advertising: Analyses of Policy Stakeholders and Supreme Court of Canada Interveners
    Western University Scholarship@Western Electronic Thesis and Dissertation Repository 6-22-2017 12:00 AM Pharmaceutical Direct-to-Consumer Advertising: Analyses of Policy Stakeholders and Supreme Court of Canada Interveners Tom T. Eldik The University of Western Ontario Supervisor Dr. Sandra Regan The University of Western Ontario Joint Supervisor Dr. Margaret Ann Wilkinson The University of Western Ontario Graduate Program in Health Information Science A thesis submitted in partial fulfillment of the equirr ements for the degree in Master of Health Information Science © Tom T. Eldik 2017 Follow this and additional works at: https://ir.lib.uwo.ca/etd Part of the Pharmacy Administration, Policy and Regulation Commons Recommended Citation Eldik, Tom T., "Pharmaceutical Direct-to-Consumer Advertising: Analyses of Policy Stakeholders and Supreme Court of Canada Interveners" (2017). Electronic Thesis and Dissertation Repository. 4633. https://ir.lib.uwo.ca/etd/4633 This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of Scholarship@Western. For more information, please contact [email protected]. Abstract Background: Pharmaceutical direct-to-consumer advertising (DTCA) is a controversial form of advertising that markets prescription pharmaceuticals to patients and consumers. The positions, power, interests and influence of pharmaceutical DTCA stakeholders shape Canadian DTCA policies; however, no focused analysis of DTCA stakeholders has occurred. Methods: This study involved a two-pronged stakeholder analysis: First was a broad analysis of pharmaceutical DTCA stakeholders using Canadian publicly available documents and websites. The second analyzed interveners on pharmaceutical litigation at the Supreme Court of Canada, and the comparisons to a leading tobacco advertising case, RJR-MacDonald v Canada (A.G) and a pharmaceutical DTCA case CanWest Media Works Inc.
    [Show full text]
  • Case Study of the Psi Social Marketing Program in Cameroon
    CASE STUDY OF THE PSI SOCIAL MARKETING PROGRAM IN CAMEROON POPTECH Report No. 97-113-061 May 1998 by Alan Handyside Regina Dennis Alpha Sy Prepared for Edited and Produced by U.S. Agency for International Development Population Technical Assistance Project Bureau for Global Programs 1611 North Kent Street, Suite 508 Office of Population Arlington, VA 22209 USA Contract No. CCP-3024-Q-00-3012 Phone: 703/247-8630 Project No. 936-3024 Fax: 703/247-8640 E-mail: [email protected] The observations, conclusions, and recommendations set forth in this document are those of the authors alone and do not represent the views or opinions of POPTECH, BHM International, The Futures Group International, or the staffs of these organizations. TABLE OF CONTENTS LIST OF ABBREVIATIONS .............................................................................................................. v EXECUTIVE SUMMARY............................................................................................................... vii LESSONS LEARNED........................................................................................................................xv 1. BACKGROUND ON AIDS................................................................................................... 1 1.1 Methodology............................................................................................................... 1 1.2 AIDS Worldwide........................................................................................................ 2 1.3 African Seroprevalence
    [Show full text]
  • Pharmaceutical Companies Need a Dose of Corporate Social Responsibility
    Minnesota Journal of Law, Science & Technology Volume 9 Issue 2 Article 7 2008 Side Effects of Corporate Greed: Pharmaceutical Companies Need a Dose of Corporate Social Responsibility Martin L. Hirsch Follow this and additional works at: https://scholarship.law.umn.edu/mjlst Recommended Citation Martin L. Hirsch, Side Effects of Corporate Greed: Pharmaceutical Companies Need a Dose of Corporate Social Responsibility, 9 MINN. J.L. SCI. & TECH. 607 (2008). Available at: https://scholarship.law.umn.edu/mjlst/vol9/iss2/7 The Minnesota Journal of Law, Science & Technology is published by the University of Minnesota Libraries Publishing. MARTIN L. HIRSCH, "AUTHENTIC HAPPINESS, SELF-KNOWLEDGE AND LEGAL POLICY," 9(2) MINN. J.L. SCI. & TECH. 607-636 (2008). Side Effects of Corporate Greed: Pharmaceutical Companies Need a Dose of Corporate Social Responsibility Martin L. Hirsch* I. INTRODUCTION “The point is, ladies and gentleman, that greed . for lack of a better word . is good. Greed is right. Greed works. Greed clarifies, cuts through, and captures the essence of the evolutionary spirit.”1 When it comes to health care and pharmaceuticals, greed is not good. In the world of health care, where patients rely on their doctors to do what is best for them, there is no place for greed.2 Corporate governance in pharmaceutical companies that focuses on the shareholder’s bottom line is completely inconsistent with health care, medicine and access to pharmaceuticals, where the patient should come first.3 This Article discusses how the corporate governance of pharmaceutical companies negatively affects health care and access to medicine world wide.4 *© 2008 Martin L.
    [Show full text]
  • Towards a Theoretical Model on Medicines As a Health Need
    Social Science & Medicine 178 (2017) 167e174 Contents lists available at ScienceDirect Social Science & Medicine journal homepage: www.elsevier.com/locate/socscimed Towards a theoretical model on medicines as a health need Claudia Marcela Vargas-Pelaez a, b, Luciano Soares c, Marina Raijche Mattozo Rover a, Carine Raquel Blatt d, Aukje Mantel-Teeuwisse b, Francisco Augusto Rossi Buenaventura e, Luis Guillermo Restrepo e, María Cristina Latorre e, Jose Julian Lopez f, * María Teresa Bürgin g, Consuelo Silva h, Silvana Nair Leite a, Farias Mareni Rocha a, a Programa de pos-graduaç ao~ em Farmacia, Universidade Federal de Santa Catarina, Campus Universitario Trindade e Florianopolis, Santa Catarina, Brazil b WHO Collaborating Centre for Pharmaceutical Policy & Regulation, Utrecht Institute for Pharmaceutical Sciences (UIPS), David de Wied Building, Universiteitsweg 99, Utrecht, The Netherlands c Programa de Pos-Graduaç ao~ em Saúde e Meio Ambiente, Universidade da Regiao~ de Joinville e Univille, Rua Paulo Malschitzki, 10 - Bom Retiro, Joinville, Santa Catarina, Brazil d Departamento de Farmacoci^encias, Universidade Federal de Ci^encias da Saúde de Porto Alegre, Rua Sarmento Leite, 245 - Cidade Baixa, Porto Alegre, Rio Grande do Sul, Brazil e Fundacion IFARMA, Colombia,^ Carrera 13 # 32-51, Torre 3 Oficina 1116, Bogota, Colombia f Departamento de Farmacia, Universidad Nacional de Colombia, Carrera 30 No. 45-03, Edificio 450, Oficina 214, Bogota D.C., Colombia g Independent researcher h Escuela Latinoamericana de Postgrados (ELAP) e Universidad de Artes y Ciencias Sociales (Arcis), Erasmo Escala 2728, Santiago, Chile article info abstract Article history: Medicines are considered one of the main tools of western medicine to resolve health problems.
    [Show full text]
  • The Pharmaceutical Industry and the TRIPS Uruguay Round Negotiations, 9 Law & Bus
    Law and Business Review of the Americas Volume 9 | Number 4 Article 3 2003 Impact of Multinational Enterprises on Multilateral Rule Making: The hP armaceutical Industry and the TRIPS Uruguay Round Negotiations Mohamad Omar Gad Follow this and additional works at: https://scholar.smu.edu/lbra Recommended Citation Mohamad Omar Gad, Impact of Multinational Enterprises on Multilateral Rule Making: The Pharmaceutical Industry and the TRIPS Uruguay Round Negotiations, 9 Law & Bus. Rev. Am. 667 (2003) https://scholar.smu.edu/lbra/vol9/iss4/3 This Article is brought to you for free and open access by the Law Journals at SMU Scholar. It has been accepted for inclusion in Law and Business Review of the Americas by an authorized administrator of SMU Scholar. For more information, please visit http://digitalrepository.smu.edu. IMPACT OF MULTINATIONAL ENTERPRISES ON MULTILATERAL RULE MAKING: THE PHARMACEUTICAL INDUSTRY AND THE TRIPS URUGUAY ROUND NEGOTIATIONS Mohamed Omar Gad* I. INTRODUCTION HE history of the negotiation of the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS Agreement)' and the context within which its initiation and progress occurred have been the subject of numerous legal and non-legal studies. 2 In a significant number of those accounts, the discourse acknowledges that the rule mak- ing process of the TRIPS Agreement and more notably the background to this rule making process in terms of domestic, unilateral and bilateral developments in the area of intellectual property (IP) protection has been disproportionately influenced by the interests of Industrialised Countries' (ICs) corporate actors. 3 Corporate interests with a stake in a *Mohamed Omar Gad is a member of the Egyptian Foreign Service, serving as Second Secretary at the Ministry of Foreign Affairs.
    [Show full text]
  • PREVENTING DRUG PRICE GOUGING: GOVERNMENT POWER and INITIATIVES Sydney Reed
    (6) FINAL MACRO VERSION - SYDNEY REED ARTICLE (PP. 165-194) (DO NOT DELETE) 3/9/2020 9:49 AM 19 Hous. J. Health L. & Policy 167 Copyright © 2019 Sydney Reed Houston Journal of Health Law & Policy PREVENTING DRUG PRICE GOUGING: GOVERNMENT POWER AND INITIATIVES Sydney Reed INTRODUCTION .......................................................................................... 169 I. BACKGROUND ........................................................................................ 169 A. Media Attention on the Issue ................................................ 169 B. Effects of High and Increasing Cost of Drugs ...................... 170 1. Effects of High and Increasing Cost of Drugs on the Cost of Healthcare as a Whole ...................................... 170 2. Effects of High and Increasing Cost of Drugs on Individuals ....................................................................... 171 C. Difficulty of Pricing Drugs and Lack of Consumer Purchasing Power ................................................................. 172 II. CURRENT FEDERAL REGULATION, ACTION, AND INACTION ............. 174 A. Congressional Action .............................................................. 174 B. Executive Action ...................................................................... 175 C. FDA Action ............................................................................... 176 1. Publication of Drugs without Approved Generics to Boost Market Competition ............................................ 178 2. Priority Review to Reduce
    [Show full text]
  • Addressing the Prescription Drug Affordability Crisis: a Golden Opportunity for State Lawmakers
    FAMILIESUSA.ORG Addressing the Prescription Drug Affordability Crisis: A Golden Opportunity for State Lawmakers Prescription drug affordability is a top concern for U.S. voters across the political spectrum and throughout the nation. While the federal government and Congress continue to debate the issue, state lawmakers can and should take the matter into their own hands. Establishing an independent body to assess such as groceries or heating in the winter.2 The prescription drug affordability is a new option for problem has become so acute that nearly one in states that has the potential to significantly curtail three adults does not take the medicine they need prescription drug pricing abuses and lower costs for due to costs, and many individuals even report cutting families, taxpayers, and businesses. Lawmakers in a dose in half or not filling a prescription.3 Maine and Maryland already have enacted versions of In the last 12 months, considerable media attention such legislation. has focused on potential action by Congress to This fact sheet provides a brief overview of the urgent address abusive drug pricing, including through need for state action on prescription drug prices, and Medicare negotiation.4 The outcome of federal efforts, key insights about this potentially powerful approach however, remains uncertain. to tackling the issue. State lawmakers have the ability and the overwhelming support of their constituents to How the Pharmaceutical Industry’s act to solve this problem. For example, in national Extreme Prices Are Affecting Your polls, nearly nine in 10 voters support allowing Constituents the government to negotiate directly with drug Unjustified, excessive drug price increases hurt manufacturers to lower prescription drug prices, more than the patients who rely on the medications.
    [Show full text]
  • T Hoen, 35 “3 by 5”, 29 301 Watch List, 34 3TC, 90 a Aaron Diamond AIDS
    Index ‘t Hoen, 35 antiretroviral therapy, 22 “3 by 5”, 29 Apotex, 155 301 Watch List, 34 apportionment, 44 3TC, 90 Argentina, 158, 342 A Article 30, 31, 42, 190 Ashraf Ghani, 292 Aaron Diamond AIDS Research Center, Asians and Pacific Islanders, 79 324 Atripla, 317 Abbott Laboratories, 48, 161 attempted murder conviction, 334 ABC approach, 129 Aurobindo, 159 absenteeism, 99 Australia, 55 Absolute Component Summed Index, 212 Avahan, 255 Abstinence, 14, 129 avian influenza, 58 abusive relationships, 328, 336 Awareness of HIV status, 313 accumulation, 118 AZT, 68 actors, 106 B actresses, 106 Actuarial projections, 81 bacillary angiomatosis, 8 adenovirus, 6 bacterial sexually transmitted infections, adequate remuneration, 42, 154 112 adherence to treatment, 315 balance between producers and users of administrative burden, 259 patented products, 207 adolescents, 133 balance of payments, 142 adult mortality, 123 Bangkok, 46, 312 Africa, 9 Bangladesh, 312 African Development Bank, 223 bargaining power, 18 African-Americans, 79, 303 Bayer, 155 age of consent, 329 Be Faithful, 129 aggravated assault, 335 behavioral change, 235, 305 Agricultural production, 30 behavioral responses to HIV/AIDS, 14 agricultural production process, 117 Bell, Devarajan, and Gersbach, 116 AIDS drugs, 31 Best Practice AIDS Standard, 250 AIDS prevention activities, 103 best practices, 225 airline traffic, 3 bilateral donors, 217 Al Gore, 30 Bill & Melinda Gates Foundation, 255 alternative livelihoods, 330 Black Death, 6, 116 Aluvia, 51, 161 Black markets, 204 Amendment
    [Show full text]